Cargando…

Targeting mutant estrogen receptors

A drug used in hormone replacement therapy can target estrogen receptors that have become resistant to breast cancer treatments.

Detalles Bibliográficos
Autores principales:	Wardell, Suzanne E, Norris, John D, McDonnell, Donald P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2019
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335051/ https://www.ncbi.nlm.nih.gov/pubmed/30648967 http://dx.doi.org/10.7554/eLife.44181

Ejemplares similares

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers
por: Raj, Ganesh V, et al.
Publicado: (2017)

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

Differential impact of the expression of the androgen receptor by age in estrogen receptor–positive breast cancer
por: Tokunaga, Eriko, et al.
Publicado: (2013)

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
por: Joseph, James D, et al.
Publicado: (2016)

Heat shock factor 1 (HSF1) cooperates with estrogen receptor α (ERα) in the regulation of estrogen action in breast cancer cells
por: Vydra, Natalia, et al.
Publicado: (2021)

Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
por: Joseph, James D, et al.
Publicado: (2019)

Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice
por: Zhang, Zhi, et al.
Publicado: (2021)

LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors
por: Maire, Virginie, et al.
Publicado: (2018)

FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer
por: Wang, Jinhua, et al.
Publicado: (2016)

Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
por: Natale, Christopher A, et al.
Publicado: (2018)

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine
por: Levin, Maren K, et al.
Publicado: (2015)

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
por: Verissimo, Carla S, et al.
Publicado: (2016)

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers
por: Defour, Jean-Philippe, et al.
Publicado: (2023)

Clinical candidate and genistein analogue AXP107‐11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein‐coupled estrogen receptor signaling
por: Mesmar, Fahmi, et al.
Publicado: (2019)

Rational design of an estrogen receptor mutant with altered DNA-binding specificity
por: Nguyen, Denis, et al.
Publicado: (2007)

Proteomic profiling of FBXW7‐mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target
por: Urick, Mary Ellen, et al.
Publicado: (2020)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies
por: Hwang, Justin H, et al.
Publicado: (2022)

Mutant SF3B1 promotes malignancy in PDAC
por: Simmler, Patrik, et al.
Publicado: (2023)

Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells
por: Luce, Audrey, et al.
Publicado: (2009)

Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs
por: Cuevas-Navarro, Antonio, et al.
Publicado: (2022)

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies
por: Agrawal, Amit, et al.
Publicado: (2015)

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
por: Zeng, Hao, et al.
Publicado: (2019)

Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen
por: Owens, Gemma L., et al.
Publicado: (2017)

New small‐molecule compound Hu‐17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells
por: Xi, Yang, et al.
Publicado: (2020)

Mammary tumor growth and metastasis are reduced in c‐Kit mutant Sash mice
por: He, Licai, et al.
Publicado: (2016)

Chemotherapy and terminal skeletal muscle differentiation in WT1‐mutant Wilms tumors
por: Royer‐Pokora, Brigitte, et al.
Publicado: (2018)

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
por: Cato, Laura, et al.
Publicado: (2017)

A regulatory mutant on TRIM26 conferring the risk of nasopharyngeal carcinoma by inducing low immune response
por: Lyu, Xiao‐Ming, et al.
Publicado: (2018)

GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
por: Jiang, Kaili, et al.
Publicado: (2021)

Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms
por: Chan, Gary KL, et al.
Publicado: (2023)

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
por: Krall, Elsa B, et al.
Publicado: (2017)

Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma
por: Forsbring, Monika, et al.
Publicado: (2009)

Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants
por: Blanden, Adam R, et al.
Publicado: (2020)

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
por: Krall, Elsa Beyer, et al.
Publicado: (2017)

Estrogen-regulated feedback loop limits the efficacy of estrogen receptor–targeted breast cancer therapy
por: Xiao, Tengfei, et al.
Publicado: (2018)

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
por: Wang, Hui Qin, et al.
Publicado: (2017)

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER(+) Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
por: Lawson, Mandy, et al.
Publicado: (2023)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k1dnkasegerdvk18k6titj5jbd